Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



麗珠醫藥集團股份有限公司 LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

POLL RESULTS OF THE ANNUAL GENERAL MEETING FOR THE YEAR 2021, THE 2022 FIRST CLASS MEETING OF A SHAREHOLDERS AND THE 2022 FIRST CLASS MEETING OF H SHAREHOLDERS HELD ON 20 MAY 2022

The board of directors (the "Board") of 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.*(the "Company") hereby announced that at the Annual General Meeting for the Year 2021 (the "AGM"), the 2022 First Class Meeting of A Shareholders (the "Class Meeting of A Shareholders") and the 2022 First Class Meeting of H Shareholders (the "Class Meeting of H Shareholders") (collectively, the "Meetings") held on 20 May 2022 at the Conference Room on the 6th Floor of Headquarters Building, 38 Chuangye North Road, Jinwan District, Zhuhai, Guangdong Province, China, all the proposed resolutions as set out in the notices of the Meetings were duly passed by the Shareholders of the Company by way of poll.

Details of the resolutions considered at the Meetings were set out in the circular of the Company dated 27 April 2022 (the "Circular"). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

As at the record date of the Meetings, the total number of shares of the Company in issue was 934,877,313 shares, which comprises of 625,046,096 A Shares and 309,831,217 H Shares. Accordingly, Shareholders (or authorized proxies) who hold a total of 934,877,313 shares of the Company were entitled to attend and vote on the resolutions proposed at the AGM; and Shareholders (or authorized proxies) who hold a total of 625,046,096 A Shares and who hold a total of 309,831,217 H Shares were entitled to attend and vote on the resolutions proposed at the Class Meeting of A Shareholders and Class Meeting of H Shareholders, respectively.

To the best of the Directors' knowledge, information and belief and having made all reasonable enquiries, there were no restrictions on any Shareholders for casting votes on the resolutions proposed at the Meetings and none of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions at the Meetings. No Shareholders are required under the Hong Kong Listing Rules to abstain from voting on any of the resolutions at the Meetings.

ATTENDANCE OF THE MEETINGS

(I) Attendance at the AGM:

Set out below are the details of the Shareholders and authorized proxies present at the AGM:

Number of Shareholders and authorized proxies	68
Including: Number of A Shareholders and authorized proxies	67
Number of H Shareholders and authorized proxies	1
Total number of Shares carrying voting rights (shares)	471,892,998
Including: Total number of A Shares of the Company carrying voting rights held by A	268,594,413
Shareholders and authorized proxies (shares)	
Total number of H Shares of the Company carrying voting rights held by H	203,298,585
Shareholders and authorized proxies (shares)	
Percentage of the total number of Shares of the Company carrying voting rights (%)	50.48%
Including: Total number of shares carrying voting rights held by A Shareholders and authorized	28.73%
proxies as a percentage of the total number of Shares of the Company (%)	
Total number of shares carrying voting rights held by H Shareholders and authorized	21.75%
proxies as a percentage of the total number of Shares of the Company (%)	

(II) Attendance at the Class Meeting of A Shareholders

Set out below are the details of the A Shareholders and authorized proxies present at the Class Meeting of A Shareholders:

Number of A Shareholders and authorized proxies	67
Total number of A Shares carrying voting rights (shares)	268,594,413
Total number of shares carrying voting rights held by A Shareholders and authorized proxies as	42.97%
a percentage of the total number of A Shares of the Company (%)	

(III) Attendance at the Class Meeting of H Shareholders:

Set out below are the details of the H Shareholders and authorized proxies present at the Class Meeting of H Shareholders:

Number of H Shareholders and authorized proxies	1
Total number of H Shares carrying voting rights (shares)	203,293,785
Total number of shares carrying voting rights held by H Shareholders and authorized proxies as	65.61%
a percentage of the total number of H Shares of the Company (%)	

POLL RESULTS OF THE RESOLUTIONS PROPOSED AT THE MEETINGS

(1) Poll results of the AGM are as follows:

Resolutions	Category of shares	Number of Shares with voting rights held by Shareholders present at the meeting	Number of Shares	Approximate ppercentage (%) of total number of Shares with voting rights held by Shareholders present at the meeting	Number of Shares	Approximate ppercentage (%) of total number of Shares with voting rights held by Shareholders present at the meeting	Number of Shares	Approximate ppercentage (%) of total number of Shares with voting rights held by Shareholders present at the meeting
nary Resolutions								
To consider and enprove the work	Total	471,892,998	471,416,498	99.8990%	291,000	0.0617%	185,500	0.0393%
report of the Board of the	A shares	268,594,413	268,503,813	99.9663%	63,900	0.0238%	26,700	0.0099%
Company for the year 2021.	H shares	203,298,585	202,912,685	99.8102%	227,100	0.1117%	158,800	0.0781%
To consider and approve the work report of the supervisory committee of the Company for the year 2021.	Total	471,892,998	471,416,498	99.8990%	291,000	0.0617%	185,500	0.0393%
	A shares	268,594,413	268,503,813	99.9663%	63,900	0.0238%	26,700	0.0099%
	H shares	203,298,585	202,912,685	99.8102%	227,100	0.1117%	158,800	0.0781%
To consider and approve the financial accounts report of the Company for the year 2021.	Total	471,892,998	471,431,298	99.9022%	291,000	0.0617%	170,700	0.0362%
	A shares	268,594,413	268,518,613	99.9718%	63,900	0.0238%	11,900	0.0044%
	H shares	203,298,585	202,912,685	99.8102%	227,100	0.1117%	158,800	0.0781%
To consider and approve the 2021	Total	471,892,998	471,416,498	99.8990%	291,000	0.0617%	185,500	0.0393%
annual report of 麗珠醫藥集團股份 有限公司 Livzon	A shares	268,594,413	268,503,813	99.9663%	63,900	0.0238%	26,700	0.0099%
Pharmaceutical Group Inc*.	H shares	203,298,585	202,912,685	99.8102%	227,100	0.1117%	158,800	0.0781%
To consider and approve the re-	Total	471,892,998	470,587,561	99.7234%	1,305,237	0.2766%	200	0.00004%
appointment of Grant Thornton (Special General Partnership) as the auditor of the Company for the year 2022 and fix its remuneration.	A shares	268,594,413	267,648,608	99.6479%	945,605	0.3521%	200	0.0001%
	H shares	203,298,585	202,938,953	99.8231%	359,632	0.1769%	0	0.0000%
	To consider and approve the work eport of the Board of the Company for the year 2021. To consider and approve the work eport of the supervisory committee of the Company for the year 2021. To consider and approve the cinancial accounts report of the Company for the year 2021. To consider and approve the 2021 annual report of 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc*. To consider and approve the responitment of Grant Thornton Special General Partnership) as the auditor of the Company for the year 2022 and fix its	Total A shares Company for the year 2021. To consider and approve the work eport of the supervisory committee of the Company for the year 2021. To consider and approve the work eport of the Supervisory committee of the Company for the year 2021. To consider and approve the financial accounts report of the Company for the year 2021. To consider and approve the 2021 H shares To consider and approve the 2021 Immual report of 歷珠醫藥集團股份有限公司Livzon中armaceutical Group Inc*. To consider and approve the responding and approve the	Total 471,892,998 A shares 268,594,413 H shares 203,298,585 To consider and approve the work eport of the supervisory committee of the Company for the year 2021. To consider and approve the work eport of the supervisory committee of the Company for the year 2021. To consider and approve the financial accounts report of the Company for the year 2021. To consider and approve the company for the year 2021. To consider and approve the 2021 multiple for the graph of the year 2022 and fix its To consider and approve the responsible auditor of the Company for the year 2022 and fix its To consider and approve the responsible auditor of the Company for the year 2022 and fix its	Total 471,892,998 471,416,498 A shares 268,594,413 268,503,813 Total 471,892,998 471,416,498 A shares 203,298,585 202,912,685 To consider and approve the work eport of the supervisory committee of the Company for he year 2021. Total 471,892,998 471,416,498 A shares 268,594,413 268,503,813 H shares 268,594,413 268,503,813 To consider and approve the mancial accounts report of the Company for the year 2021. Total 471,892,998 471,431,298 To consider and approve the Company for the year 2021. Total 471,892,998 471,416,498 A shares 268,594,413 268,518,613 H shares 203,298,585 202,912,685 To consider and approve the 2021 Total 471,892,998 471,416,498 A shares 268,594,413 268,503,813 Dharmaceutical Group Inc*. Total 471,892,998 470,587,561 To consider and approve the responsible of Grant Thornton Special General Partnership) as he auditor of the Company for the year 2022 and fix its Total 471,892,998 470,587,561 A shares 268,594,413 268,503,813 268,503,813 268,503,813	Total 471,892,998 471,416,498 99.8990% 471,416,498 99.8990% 471,416,498 99.8990% 471,416,498 99.8990% 471,416,498 99.8990% 471,416,498 99.8990% 471,416,498 99.8990% 471,416,498 99.8990% 471,416,498 99.8990% 471,416,498 99.8990% 471,416,498 99.8990% 471,416,498 99.8990% 471,416,498 99.8990% 471,416,498 99.8990% 471,431,298 471,4	Total 471,892,998 471,416,498 99.8990% 291,000 Coonsider and approve the work eport of the Board of the Company for the year 2021. H shares 203,298,585 202,912,685 99.8102% 227,100 Fo consider and approve the work eport of the supervisory committee of the Company for the year 2021. H shares 203,298,585 202,912,685 99.8102% 227,100 Fo consider and approve the financial accounts report of the Company for the year 2021. Total 471,892,998 471,416,498 99.8990% 291,000 Fo consider and approve the financial accounts report of the Company for the year 2021. Total 471,892,998 471,431,298 99.9022% 291,000 Fo consider and approve the ginancial accounts report of the Company for the year 2021. Total 471,892,998 471,416,498 99.8990% 291,000 Fo consider and approve the 2021 the shares 203,298,585 202,912,685 99.8102% 227,100 Fo consider and approve the 2021 the shares 203,298,585 202,912,685 99.8102% 227,100 Fo consider and approve the repopointment of Grant Thornton Special General Partnership) as the auditor of the Company for the year 2022 and fix its Total 471,892,998 470,587,561 99.7234% 1,305,237 Fo consider and approve the repopointment of Grant Thornton Special General Partnership) as the auditor of the Company for the year 2022 and fix its Total 471,892,998 470,587,561 99.7234% 1,305,237 For consider and approve the repopointment of Grant Thornton Special General Partnership) as the auditor of the Company for the year 2022 and fix its Total 471,892,998 470,587,561 99.7234% 1,305,237 For consider and approve the repopointment of Grant Thornton Special General Partnership) as the auditor of the Company for the year 2022 and fix its Total 471,892,998 470,587,561 99.7234% 1,305,237 For consider and approve the repopointment of Grant Thornton Special General Partnership) as the auditor of the Company for the year 2022 and fix its Total 471,892,998 470,5	Total 471,892,998 471,416,498 99.8990% 291,000 0.0617%	Total 471,892,998 471,416,498 99,8990% 291,000 0.0617% 185,500

As votes cast for all the above ordinary resolutions were more than one-half of the valid voting rights of Shareholders (including authorized proxies) present at the AGM, all the above ordinary resolutions were duly passed as ordinary resolutions

				Fo	r		ainst	Abstain	
No.	Resolutions	Category of shares	Number of Shares with voting rights held by Shareholders present at the meeting	Number of Shares	Approximate ppercentage (%) of total number of Shares with voting rights held by Shareholders present at the meeting	Number of Shares	Approximate ppercentage (%) of total number of Shares with voting rights held by Shareholders present at the meeting	Number of Shares	Approximate ppercentage (%) of total number of Shares with voting rights held by Shareholders present at the meeting
Spec	cial Resolutions								
	To consider and approve the 2021	Total	471,892,998	471,539,227	99.9250%	353,571	0.0749%	200	0.00004%
6	To consider and approve the 2021 Annual Profit Distribution Plan of the Company.	A shares	268,594,413	268,540,413	99.9799%	53,800	0.0200%	200	0.0001%
		H shares	203,298,585	202,998,814	99.8525%	299,771	0.1475%	0	0.0000%
	To consider and approve the Company's facility financing and provision of financing guarantees to its subsidiaries.	Total	471,892,998	463,660,996	98.2555%	8,231,802	1.7444%	200	0.00004%
7		A shares	268,594,413	260,362,411	96.9352%	8,231,802	3.0648%	200	0.0001%
		H shares	203,298,585	203,298,585	100.0000%	0	0.0000%	0	0.0000%
	To consider and approve the grant of general mandate to the Board for issuing of shares.	Total	471,892,998	439,540,621	93.1441%	32,337,277	6.8527%	15,100	0.0032%
8		A shares	268,594,413	267,187,383	99.4762%	1,391,930	0.5182%	15,100	0.0056%
		H shares	203,298,585	172,353,238	84.7784%	30,945,347	15.2216%	0	0.0000%
	To consider and approve the grant	Total	471,892,998	471,804,898	99.9813%	73,100	0.0155%	15,000	0.0032%
9	of general mandate to the Board to repurchase H shares of the Company.	A shares	268,594,413	268,506,313	99.9672%	73,100	0.0272%	15,000	0.0056%
		H shares	203,298,585	203,298,585	100.0000%	0	0.0000%	0	0.0000%
	To consider and approve the draft	Total	471,892,998	469,107,028	99.4096%	2,785,770	0.5903%	200	0.00004%
10	and summary of the second phase ownership scheme under the Medium to Long-term Business	A shares	268,594,413	267,347,700	99.5358%	1,246,513	0.4641%	200	0.0001%
	Partner Share Ownership Scheme of the Company.	H shares	203,298,585	201,759,328	99.2429%	1,539,257	0.7571%	0	0.0000%

				For	r	Aga	ninst	Abs	tain	
No.	Resolutions	Category of shares	Number of Shares with voting rights held by Shareholders present at the meeting	Number of Shares	Approximate ppercentage (%) of total number of Shares with voting rights held by Shareholders present at the meeting	Number of Shares	Approximate ppercentage (%) of total number of Shares with voting rights held by Shareholders present at the meeting	Number of Shares	Approximate ppercentage (%) of total number of Shares with voting rights held by Shareholders present at the meeting	
	To consider and approve the administrative measures of the second phase ownership scheme	Total	471,892,998	469,099,828	99.4081%	2,792,970	0.5919%	200	0.00004%	
11	under the Medium to Long-term Business Partner Share	A shares	268,594,413	267,340,500	99.5332%	1,253,713	0.4668%	200	0.0001%	
	Ownership Scheme of the Company.	H shares	203,298,585	201,759,328	99.2429%	1,539,257	0.7571%	0	0.0000%	
	To consider and approve the authorization to the Board to deal with matters regarding the second	Total	471,892,998	469,107,028	99.4096%	2,785,770	0.5903%	200	0.00004%	
12	phase ownership scheme under the Medium to Long-term	A shares	268,594,413	267,347,700	99.5358%	1,246,513	0.4641%	200	0.0001%	
	Business Partner Share Ownership Scheme of the Company.	H shares	203,298,585	201,759,328	99.2429%	1,539,257	0.7571%	0	0.0000%	
	As votes cast for all the above special resolutions were more than two-thirds of the valid voting rights of Shareholders (including authorized proxies) present at the AGM, all the									

above special resolutions were duly passed as special resolutions at the AGM.

(2) Poll results of the Class Meeting of A Shareholders are as follows:

				Fo	or	Aga	ainst	Abstain	
No.	Resolutions	Category of Shares	Number of Shares with voting rights held by Shareholders present at the meeting	Number of Shares	Percentage (%) of number of Shares with voting rights held by Shareholders present at the meeting	Number of Shares	Percentage (%) of number of Shares with voting rights held by Shareholders present at the meeting	Number of Shares	Percentage (%) of number of Shares with voting rights held by Shareholders present at the meeting
Spe	cial Resolution								
1	To consider and approve the grant of general mandate to the Board to repurchase H shares of the Company.	A Shares	268,594,413	267,187,383	99.4762%	1,391,930	0.5182%	15,100	0.0056%
	As votes cast for the above resolution. Shareholders, the above resolution						rized proxies) prese	ent at the Class M	eeting of A

(3) Poll results of the Class Meeting of H Shareholders are as follows:

				Fo	or	Against		Abstain	
No.	Resolutions	Category of Shares	Number of Shares with voting rights held by Shareholders present at the meeting	Number of Shares	Percentage (%) of number of Shares with voting rights held by Shareholders present at the meeting	Number of Shares	Percentage (%) of number of Shares with voting rights held by Shareholders present at the meeting	Number of Shares	Percentage (%) of number of Shares with voting rights held by Shareholders present at the meeting
Spec	cial Resolution								
1	To consider and approve the grant of general mandate to the Board to repurchase H shares of the Company.		203,293,785	203,288,785	99.9975%	0	0.0000%	5,000	0.0025%
	As votes cast for the above resolution. Shareholders, the above resolution.						rized proxies) preso	ent at the Class M	eeting of H

Grant Thornton (Special General Partnership) acted as the scrutineer for the vote-taking at the Meetings. The Company's PRC legal advisor, D&S Law Firm (廣東德賽律師事務所), two representatives of Shareholders and a representative of supervisors of the Company also jointly acted as the scrutineers for the vote-taking of the poll at the Meetings.

LEGAL OPINION ISSUED BY LAWYERS

Delegated lawyers from D&S Law Firm witnessed the Meetings and issued the "Legal Opinions of D&S Law Firm on AGM, Class Meeting of A Shareholders and Class Meeting of H Shareholders of Livzon Pharmaceutical Group Inc. (《廣東德賽律師事務所關於麗珠醫藥集團股份有限公司二零二一年度股東大會、二零二二年第一次 A 股類別股東會及二零二二年第一次 H 股類別股東會的法律意見書》)", certifying that: "The convening and procedures of the Meetings comply with the requirements of laws, regulations and Articles of Association, the qualifications of personnels who attended the Meetings, the qualifications of the conveners and the voting procedure of the Meetings are legal and effective, and the voting results of the resolutions at the Meetings are legal and effective."

SPECIAL NOTICE

There was neither objection to the proposed resolutions of the Meetings, nor changes to the resolutions of the previous general meetings at the Meetings.

CASH DIVIDEND AND BONUS ISSUE

The Meetings has approved to distribute cash dividend of RMB13.00 (tax inclusive) for every 10 shares to all Shareholders of the Company, based on the Company's total share capital (excluding the shares of the Company which were repurchased but not yet cancelled) as at the registration date of shareholding as determined by implementation of the 2021 annual profit distribution plan. There will be no bonus shares, nor will the capital reserves be capitalized.

The Cash Dividend will be distributed to Shareholders whose names are on the register of the Shareholders of the Company on Wednesday, 1 June 2022. The aforementioned Cash Dividend will be denominated and declared in RMB and will be distributed in RMB to the A Shareholders of the Company and in HKD to H Shareholders, using the middle exchange rates for RMB to HKD (i.e. HKD1.00 to RMB0.86004) as published by the People's Bank of China on the date of the AGM (Friday, 20 May 2022) as the exchange rate, being a Cash Dividend of approximately HKD1.51156 per H Share (tax inclusive). Relevant cheques of the Cash Dividend will be despatched on or before Friday, 24 June 2022 to the H Shareholders entitled to receive such Cash Dividend by ordinary post at their own risk.

The record date for determining the qualification of the H Shareholders for the proposed distribution of the Cash Dividend will be Wednesday, 1 June 2022. In order to be qualified for the proposed distribution of the Cash Dividend, H Shareholders who are not yet registered must lodge all transfers of shares accompanied by the relevant share certificates with the Company's H Share Registrar, Tricor Investor Services Limited, at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong for registration no later than 4:30 p.m. on Wednesday, 1 June 2022.

In accordance with the "Enterprise Income Tax Law of the People's Republic of China (《中華人民共和國企 業所得稅法》)" and the "Rules for the Implementation of the Enterprise Income Tax Law of the People's Republic of China (《中華人民共和國企業所得稅法實施條例》)", both became effective on 1 January 2008, and the "Notice of the State Administration of Taxation on Issues Relevant to the Withholding of Enterprise Income Tax on Dividends Paid by PRC Resident Enterprises to Offshore Non-resident Enterprise Holders of H Shares (Guo Shui Han [2008] No. 897) (《關於中國居民企業向境外 H 股非居民企業股東派發股息代扣代 繳企業所得稅有關問題的通知》 (國稅函[2008]897 號))" promulgated by the State Administration of Taxation on 6 November 2008, the Company is obliged to withhold and pay the PRC enterprise income tax on behalf of non-resident enterprise(s) at a tax rate of 10% when the Company distributes any dividends to nonresident enterprise Shareholder(s) whose names appear on the register of members for H Shares of the Company. Accordingly, any H Shares which are not registered under the name(s) of individual(s) (which, for this purpose, include H Shares registered under the name of HKSCC Nominees Limited, other nominees, trustees, or other organisations or groups) shall be deemed to be H Shares held by non-resident enterprise Shareholder(s), and the PRC enterprise income tax shall be withheld from dividends payable thereon. Non-resident enterprise Shareholders may apply for a tax refund for the difference (if any) in accordance to relevant tax laws such as tax treaty (arrangement).

In accordance with the "Circular on Certain Issues Concerning the Policies of Individual Income Tax (Cai Shui Zi [1994] No. 020) (《關於個人所得稅若干政策問題的通知》 (財稅字[1994]020 號))" promulgated by the Ministry of Finance and the State Administration of Taxation on 13 May 1994, overseas individuals are temporarily exempted from the PRC individual income tax for dividends or bonuses received from foreign invested enterprises. As the Company is a foreign-invested enterprise, the Company will not withhold and pay the individual income tax on behalf of overseas individual Shareholders whose names appear on the register of members for H Shares of the Company when the Company distributes dividends to those Shareholders.

In accordance with the "Notice of the Ministry of Finance, the State Administration of Taxation, and the China Securities Regulatory Commission on Taxation Policies concerning the Pilot Program of an Interconnection Mechanism for Transactions in the Shenzhen and Hong Kong Stock Markets (Cai Shui [2016] No. 127) (《財政 部、國家稅務總局、證監會關於深港股票市場交易互聯互通機制試點有關稅收政策的通知》(財稅 [2016]127 號))", (i) for dividends received by domestic individual investor from investing in the Company's H shares listed on the Hong Kong Stock Exchange through Shenzhen-Hong Kong Stock Connect, the Company is obliged to withhold personal income tax at a tax rate of 20% when the Company shall apply to China Securities Depository and Clearing Corporation Limited ("CSDCC") for the registrar of domestic individual investors. For dividends of the shares listed on the Hong Kong Stock Exchange received by mainland securities investment funds through the Shenzhen-Hong Kong Stock Connect, individual income tax shall be calculated in accordance with the above requirements; (ii) for dividends received by domestic enterprise investors from investing in the shares listed on the Hong Kong Stock Exchange through Shenzhen-Hong Kong Stock Connect, such amount shall be reckoned in their gross revenue and subject to corporate income tax pursuant to laws. In particular, for the dividends obtained by mainland resident enterprises from holding relevant H Shares for consecutive 12 months, the corporate income taxes shall be exempted pursuant to laws. The Company shall apply to CSDCC for the registrar of domestic individual investors. The Company will not withhold the income tax on dividend for the domestic enterprise investors, and the tax payable shall be declared and paid by the domestic enterprise investors.

For A Shareholders, the record date for Cash Dividend, payment methods and time will be announced separately on the website of the Shenzhen Stock Exchange.

By order of the Board 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc. * Yang Liang

Company Secretary

Zhuhai, China 20 May 2022

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman), Mr. Qiu Qingfeng and Mr. Yu Xiong; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Tian Qiusheng, Mr. Wong Kam Wa, Mr. Luo Huiyuan and Ms. Cui Lijie.

^{*} For identification purpose only